Notice of NIMH's Participation in PAR-17-438 "Assay development and screening for discovery of chemical probes or therapeutic agents (R01)"

Notice Number: NOT-MH-17-041

Key Dates
Release Date:  August 8, 2017

Related Announcements
PAR-17-438

Issued by
National Institute of Mental Health (NIMH)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute of Mental Health (NIMH), will participate effective immediately, in PAR-17-438, “Assay development and screening for discovery of chemical probes or therapeutic agents (R01)". The following sections have been updated to reflect the participation of NIMH in this PAR:

Part 1. Overview Information


Components of Participating Organizations
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Deafness and Other Communication Disorders (NIDCD)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)

Catalog of Federal Domestic Assistance (CFDA) Number(s) 
93.395, 93.173, 93.279, 93.855, 93.856, 93.242

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

Institute Interests
NIMH:  The NIMH is especially interested in applications for novel, clinically-relevant targets with the goal of transforming target discovery into therapeutic treatment of mental disorders such as depressive disorder, bipolar disorder, schizophrenia, anxiety disorders, panic disorder, autism, etc. (see From Discovery to Cure: Accelerating the Development of New and Personalized Interventions for Mental Illnesses). Proposed projects should be relevant to NIMH's mission of supporting basic science discoveries and translating these discoveries into new therapeutic interventions that will relieve the suffering of people with mental disorders. Investigators who are interested in developing novel and robust assays to reveal changes in neuronal and/or glial function may apply to PAR-15-066. Projects aimed at the discovery of in vivo chemical probes should consider applying to PAR-17-336. Projects aimed at the discovery of cell-based chemical probes should consider applying to PAR-17-335. Projects aimed at early stages of drug discovery and development should consider the Drug Discovery for Nervous System Disorders PAR-16-041 (R01) and PAR-16-042 (R21), National Cooperative Drug Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction PAR-17-186 (U19) and PAR-17-185 (U01). Details on these and additional funding opportunity announcements and therapeutic discovery resources are listed on the NIH/NIMH Therapeutics Discovery Research webpage. Further information on NIMH research priorities can be found in the NIMH Strategic Plan, Strategic Research Priorities, and Interventions Workgroup Report. Applicants are strongly encouraged to discuss applications with NIMH staff listed in Section VII - Agency Contact(s) Scientific/Research Contacts prior to submission to determine alignment of the planned studies with NIMH priorities and to assess whether this or other NIMH funding opportunities are most appropriate.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Yong Yao, Ph.D.
National Institute of Mental Health (NIMH)
Telephone:  301-443-6102
Email:  yyao@mail.nih.gov

Financial/Grants Management Contact(s)

Rebecca Claycamp, M.S., CRA
National Institute of Mental Health (NIMH)
Telephone:  301-443-2811
Email:  rclaycam@mail.nih.gov
  
All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Yong Yao, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-6102
Email: yyao@mail.nih.gov